Vilon

Vilon is a synthetic dipeptide composed of L-lysine and L-glutamic acid (sequence: Lys-Glu; abbreviated KE). It was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology and belongs to a class of short-chain peptide bioregulators proposed to act through direct interaction with nuclear chromatin.

The central proposed mechanism involves sequence-specific binding to double-stranded DNA, with preferential affinity for TCGA tetranucleotide sequences within promoter regions of genes governing immune signaling, cell proliferation, and cytoskeletal dynamics. This binding is thought to locally destabilize chromatin structure, reduce inhibitory methylation activity, and shift condensed heterochromatin toward the transcriptionally active euchromatin state — a process described in the Khavinson literature as deheterochromatinization.

At the transcriptional level, Vilon stimulated IL-2 gene expression in mouse spleen lymphocytes in vitro in a dose- and time-dependent manner (Khavinson et al., 2000; PMID 11177276). The authors proposed the peptide either facilitates nuclear transport of trans-acting transcription factors or functions as a structural component of their active centers, enabling IL-2 gene transcription. In a human monocyte/macrophage cell line (THP-1), Vilon inhibited LPS-induced TNF and IL-6 expression, promoted STAT-1 signaling, and induced TNF tolerance (Avolio et al., 2022; PMID 35408963), indicating context-dependent immunomodulatory rather than uniformly stimulatory effects. These proposed intranuclear mechanisms have not been confirmed by independent laboratories outside the originating research group.

The evidence base for Vilon derives predominantly from a single research group at the St. Petersburg Institute of Bioregulation and Gerontology, with publication mainly in translated Russian-language journals. Independent replication by outside institutions is sparse.

In rodent models, subcutaneous administration to female CBA mice beginning at age 6 months increased physical activity and endurance, reduced body temperature, prevented spontaneous neoplasm development, and extended lifespan with no observed adverse developmental effects (Khavinson and Anisimov, 2000; PMID 11140587; PMID 10944717). Chemically-induced carcinogenesis models produced consistent protective signals: in a rat bladder tumor model using N-butyl-N-(4-hydroxybutyl)nitrosamine, Vilon reduced tumor incidence from 75.5% in controls to 56% in treated animals (Pliss et al., 2001; PMID 11586406). In a 1,2-dimethylhydrazine mouse model at 10 µg/kg, Vilon-treated animals developed tumors at 14.3% versus 60% in controls over a 46-week observation period, with inhibition of precancerous kidney lesions also noted (Pliss et al., 2005; PMID 16308980).

A DNA microarray study in mouse heart tissue found Vilon altered expression of 36 gene clones, upregulating 157 clones by up to 6.13-fold; functional cardiac endpoints were not characterized (Anisimov et al., 2002; PMID 12360356).

The sole indexed human clinical study examined elderly patients with type 1 diabetes mellitus receiving Vilon as an adjunct to standard therapy. Results included normalization of T-lymphocyte and B-lymphocyte counts and IgA levels, optimization of coagulation hemostasis, and reduced insulin requirements in most patients (Kuznik et al., 2007; PMID 18306698). This study was small and uncontrolled, and must be interpreted with caution. A 2022 Italian-Russian in vitro study confirmed inhibition of LPS-induced TNF and IL-6 in THP-1 macrophages and induction of TNF tolerance, representing the only peer-reviewed work with non-Russian primary authorship (Avolio et al., PMID 35408963).

Typical dosage: 10-20 mg (daily for cycles).

No regulatory authority has approved Vilon for human therapeutic use, and no formal dose-finding clinical trial has been published in indexed literature.

In preclinical rodent studies, subcutaneous injection was the standard route. The chemically induced colon carcinogenesis study used 10 µg/kg subcutaneously in mice (Pliss et al., PMID 16308980). The lifespan study administered Vilon subcutaneously beginning at 6 months of age, but the precise dose was not specified in the available abstract (Khavinson et al., PMID 11140587).

In the sole indexed human clinical application — elderly diabetic patients — Vilon was administered as an adjunct to standard therapy; the exact dose and schedule were not reported in the published abstract (Kuznik et al., PMID 18306698).

Community and compounding-oriented sources, which are not peer-reviewed and should not be treated as clinical guidance, describe subcutaneous injection of 5 mg per day for 10 consecutive days, with cycles repeated once or twice per year for general immune support. Some sources cite cycles of 5 to 10 mg per day for 5 to 12 days. Oral administration is discussed in community contexts, but no pharmacokinetic or bioavailability data for the oral route appear in the indexed literature, and peptide degradation in the gastrointestinal tract is a plausible limitation.

This information is provided for educational and encyclopedic reference only and does not constitute medical advice. Vilon is not approved for human use by the FDA or EMA, is available in Western markets only as an unregulated research chemical, and its efficacy and safety in humans have not been established through controlled clinical trials.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The best-characterized combination is Vilon with Epithalon (Ala-Glu-Asp-Gly), a synthetic pineal tetrapeptide from the same Khavinson research program. Multiple published studies from this group co-administered both compounds in aged rats, examining intestinal enzyme activity (PMID 12660839), nutrient absorption (PMID 12420071), and cardiac gene expression (PMID 12360356). In the DNA microarray study, combined administration altered 144 gene clones — greater than Vilon alone (36 clones) or Epithalon alone (98 clones) — suggesting additive but partially overlapping genomic targets. These animal co-administration studies do not constitute evidence of efficacy or safety of combined use in humans.

Community and biohacking sources describe Vilon in stacks with Thymalin, a broader bovine thymic polypeptide extract, based on the rationale of complementary immune-axis activity, and with Epitalon for purported longevity protocols. These community combinations are entirely anecdotal; no controlled human data exist evaluating their combined use, and the safety implications of simultaneous immunomodulation from multiple peptide bioregulators are unknown.

Vilon is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Minimal side effects

The published preclinical safety record is limited but generally favorable within the scope of available studies. The long-term lifespan study in CBA mice explicitly reported no unfavorable effects on development, reproductive parameters, or oxidative stress markers from chronic Vilon administration (Khavinson et al., PMID 11140587). No lethal dose has been reported in the indexed literature.

In the sole indexed human study, no adverse events were noted in the published abstract, and Vilon was used alongside standard pharmaceutical care (Kuznik et al., PMID 18306698). However, the study was small and uncontrolled; absence of reported adverse events in this setting does not constitute robust safety evidence.

Because Vilon exerts bidirectional immunomodulatory effects — upregulating IL-2 in lymphocytes while suppressing TNF and IL-6 in monocytes — its safety in patients with autoimmune disorders is uncertain, with theoretical risk of disease exacerbation through enhanced T-cell activation or, conversely, impaired immune surveillance through cytokine suppression. Use alongside immunosuppressive therapy (e.g., in organ transplant recipients) has not been studied. Use in patients with active malignancy carries uncertain risk given the antiproliferative signals in animal carcinogenesis models alongside systemic immunomodulatory effects.

No safety data exist for pregnancy, lactation, or pediatric populations. Local injection-site reactions (redness, tenderness) are expected with subcutaneous peptide administration. As Vilon is sold as an unregulated research chemical in Western markets, commercial preparations are not subject to pharmaceutical-grade manufacturing controls, and purity and sterility cannot be assumed.